Autoimmunity

Arthritis Sufferers Lead the Way for Advancing Cannabis as Pain Medicine

October 10, 2019 Adult, Anti-inflammatory properties, Autoimmunity, Cannabis, Cannabis News, Cannabis Science, CED In The News, Dr Caplan, Future Medicine, Topical

A Weedmaps News piece, looking earnestly at cannabis and arthritis. As the title suggests, arthritis sufferers are, indeed, leading the way for advancing cannabis as pain medicine.

https://news.weedmaps.com/2019/10/arthritis-sufferers-lead-the-way-for-advancing-cannabis-as-pain-medicine/

“We know cannabis is a powerful anti-inflammatory agent that functions differently from other drugs like Tylenol, Ibuprofen, steroids, or the biological options that work on the immune system and can present severe side-effects,” Caplan told Weedmaps News. “We don’t see that w/ cannabis”

“There is still not enough of what modern medicine calls the gold standard- randomized trials or review trials that collect multiple studies – but anecdote is not meaningless,” Caplan said.

“Stories we hear from individuals are very meaningful and worthwhile,” Caplan said. “We live in a scientific culture that thinks we should discount anecdotes and only pay attention to the highest quality data, which I think is misleading and not fair.”

Cannabinoid Receptors Play Important Roles in Anti-inflammation, Anti-depression, Immune modulation, and HIV support

September 11, 2019 Animal Model, Anti-inflammatory properties, Anxiety, Autoimmunity, Blood-Levels, Cannabinoids, Cannabis, Cannabis Science, CB1, CB2, Dementia, Depression, Future Medicine, History, Science

Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation Review

Summary Info:

Previous research and characterization of cannabinoid receptors (CBs) have consistently demonstrated the therapeutic potential for many medical conditions. CB1, the receptor responsible for the intoxicating (and other psychoactive) effects of cannabis, has demonstrated the ability to modulate concentrations of certain other neurotransmitters, giving it the capability of acting as an antidepressant. Additionally, mice lacking CB1 receptors exhibited increased neurodegeneration, increased susceptibility for autoimmune encephalomyelitis, and inferior recovery to some traumatic nerve injuries. The CB2 receptor is generally attributed to support for modulating the immune system and calming some of the body’s natural, core inflammatory signaling systems. Activation of the receptor has been found to associate with neuroinflammatory conditions in the brain, and in appropriate circumstances, can result in the programming of cell death among some immune cells. This effect points toward a role in communication, inflammation and autoimmune diseases. Furthermore, evidence points to CB2 holding significant potential in HIV therapy. Binding partners of CB2 inhibit the HIV-1 infection and help to diminish HIV replication. Historically, these staggering findings have escaped traditional modern medical understanding. Further investigation into the therapeutic potential of cannabis, with respect to the treatment of inflammation, depression, autoimmune diseases, and HIV is at a minimum, clearly warranted for a more comprehensive understanding of effective medical therapy.

Dr Caplan and the #MDTake:

The main points here no longer seem to be investigational trends, but just pillars of Cannabis Medicine that are embarrassingly new, and poorly recognized by the modern medical establishment. While the bulk of consumers, including patients, may not engage with the science on a molecular basis, by iterative or intuitive science, individuals are diligently discovering what forms of cannabis serve their personal interests more effectively. This is, through a scientific lens, a trial-and-error adventure through products, which have various ratios of cannabinoid-receptor activation or inhibition, that ultimately achieves a similar result, which is a clinical relief for a particular ailment. Does the fact that the process does not begin with a clear understanding of the involved receptors and receptor modulators really matter? If one of the primary objectives of Medicine is to treat and/or ease suffering, and the products are built upon a bedrock of chemical safety (misuse, inappropriate, or misinformed production of products notwithstanding), it should not matter that people discover it by happy accident, or through more direct achievement.

View this review (yellow link) or download:

Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation ReviewDownload

This paper is also stored here: http://bit.ly/34CN89F inside the CED Foundation Archive

To explore related information, click the keywords below:

Psychiatric Disorders Reduce Survival Among Immune-Mediated Inflammatory Disease Patients

September 4, 2019 Adult, Aging, Anti-inflammatory properties, Anxiety, Arthritis, Autoimmunity, Bipolar Disorder, Cannabis Science, Case Study, CED Clinic, Depression, IBS, Mental Health, Multiple Sclerosis

Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases

Summary Information:

A new study finds that a diagnosis of depression, anxiety, and/or bipolar disorder increases mortality rates for patients of one of three immune-mediated inflammatory diseases (IMID):

1) multiple sclerosis (MS), or

2) inflammatory bowel disease (IBD), or

3) rheumatoid arthritis (RA).

Depression and bipolar disorder can cause poor health behaviors in patients, as depression, bipolar disorder, and anxiety disorders are “associated with increased inflammation and immune dysregulation.” Suicide risk and attempts are increased among IMID patients with mental illness, compared with IMID patients who are not also suffering from one of these additional battles. Given that cannabis has shown promise in treating both inflammation and a range of psychiatric disorders, there is reason to be optimistic for further cannabis research to uncover multifunctional treatment options.

Dr Caplan and the #MDTake:

Clinically, it’s rare to see medical patients who have only one concern. Sure, there are some who are hoping that cannabis will help them to treat seizures, headaches, anxiety, sleep troubles, or terrible back pain, but more often, it is a combination of several troubles that each add to a cumulative tipping point.

Naturally, very few individual systems act alone. When a body part is injured, sleeping (or not sleeping) effects the course of illness. Similarly, feeling less anxious, or improving sleep, may make symptoms of a struggle with consistent headaches seem more tolerable. Even when there aren’t direct connections between symptoms, a treatment which implements a systemic treatment can have multiplied benefits.

Many patients have found that cannabis offers them a way to attack more than one problem, with a single actor. Some with Diabetes are finding that some formulations are not only helping them reduce blood sugar levels, but also reducing appetite. Similarly, some patients with ADD are turning to cannabis options which may help them focus, without their ability to get to sleep at night.

To a related note, many elderly patients are treated with too many medications. Modern Western medical treatment often compels patients into silos of treatments by isolated specialists, who are not always monitoring the patient as a being beyond individual organ systems. Medications, such as cannabis, which have the opportunity to treat more than one system, without multiplying the risk of potential drug-drug interactions presents a much safer approach to care

View this review (yellow link) or download:

Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseasesDownload

This paper is also stored here: http://bit.ly/2MRDfiP inside the CED Foundation Archive

To explore related information, click the keywords below:

New Developments of Cannabinoid-Based Drugs

August 1, 2019 Adult, Anti-inflammatory properties, Autoimmunity, Behavior change, Blood-Levels, Business of Cannabis, Cannabinoids, Cannabis, Cannabis Science, Case Study, CB1, CB2, CBD, CED Foundation, Cognition, Financial Projections, Future Medicine, Hemp, History, Impairment, Memory, Mental Health, Mood, Neuropathy, Occasional Use, Opiates, Pain, Regulation, Social Justice, Stigma, Synthetic Cannabinoids, Terpenes, THC

Title: Novel approaches in clinical development of cannabinoid drugs

A pamphlet has recently been published that highlights new approaches in the clinical development of cannabinoid-based therapies. The pamphlet begins with a look into how current cannabinoids affect patients based on gender, stress, physiological variations, and also delves into how cannabis works on the body in general.

A novel therapy that features an oral version of tetrahydrocannabinol (THC) and a synthetic activator of cannabinoid-receptor-1 (CB1) is explored in this piece and frames it to be a promising future therapy. The pharmacological properties of these two novel therapies were optimized during development after various analysis techniques, forming medications that the authors hope to see in future clinical trials.

Although the authors remain hopeful that their cannabis-based therapies will reach clinical trials soon, trials featuring cannabinoids are difficult to test in a formal setting because of a dire lack of funding. The federal government still lists cannabis as a Schedule I substance, under the Controlled Substances Act, meaning that the federal government does not support the idea that cannabis has any medical use. Considering the legal status of cannabis, only privately-funded studies are able to take place, and unfortunately, that leaves cannabis research in an area of complete bias and prohibitively underfunded. Considering the massive literature supporting a myriad of novel therapeutic benefits, this is a costly reality to the health and well-being of millions.

View this review (yellow link) or download:

Novel approaches in clinical development of cannabinoid drugsDownload

This paper is also stored here: http://bit.ly/2K7bbVX inside the CED Foundation Archive

To explore related information, click the keywords below:

Video: Do-It-Yourself Cannabis Tinctures

July 17, 2019 Alcohol, Anti-inflammatory properties, Antibiotic, Antioxidant, Anxiety, Arthritis, Autism, Autoimmunity, Behavior change, Bipolar Disorder, Business of Cannabis, Cannabinoids, Cannabis, Cannabis Education, Cannabis News, Case Study, CBD, CBN, CED Clinic, CED In The News, Cognition, Colon Cancer, Cooking, Cultivation, Cultivation / Growing / Horticulture, Depression, Dermatology / Skin, Diabetes, DIY, Dosing, Dr Caplan, Edibles, Epilepsy, Extraction, Farming, Fibromyalgia, Flavonoids, Future Medicine, Gastrointestinal Effects, Hemp, History, IBS, Insomnia, Male Fertility, Memory, Mental Health, Mood, Muscle Pain, Nausea, Neuropathy, Obesity, OCD, Opiates, Oral Health, Pain, Pediatrics, Processing, Products, Prostate Cancer, Psychosis, PTSD, Schizophrenia, Seizure / Epilepsy, Sleep, Sleep Apnea, Stigma, Stress, Taste, THC, Topical, Video

One of the terrific realities of modern Cannabis is that it is possible, and often quite simple, to make effective products at home. With suitable education and access to testing facilities, the soil, nutrients, and plant growth can be supported at home, lab-tested for make-up and potency, as well as safety-checked for potential microscopic contaminants, and ultimately, individualized medicine can be created right at home!

Here is a sample instructional for just one way that cannabis tincture can be made at home. There are countless others and hopefully, many that are yet to be discovered!

To explore related information, click the keywords below:

Cannabinoids Treat Chronic Gastrointestinal Disorders

July 16, 2019 Adverse Effects, Anti-inflammatory properties, Autoimmunity, Blood-Levels, Cannabinoids, Cannabis, Cannabis Science, Case Study, CB1, CB2, CBD, Future Medicine, Gastrointestinal Effects, IBS, Nabilone, Nausea, Neuropathy, Oral Health, Pain, Stigma, Stress, Synthetic Cannabinoids, THC

Title: Nabilone administration in refractory chronic diarrhea- a case series

A new study reveals the efficacy of treating chronic gastrointestinal disorders with cannabinoids, such as Nabilone. Researchers followed case studies in which patients were given nabilone which greatly reduced symptoms of chronic diarrhea and weight gain, over a period of three months.

The cannabinoid treatment also reduced the abdominal pain felt by patients and improved their overall quality of life. Considering the favorable safety profile of cannabinoids and the effectiveness demonstrated in the patients, cannabinoids were deemed an appropriate and clinically beneficial method for the treatment of chronic gastrointestinal disorders, such as chronic diarrhea.

Highlighted by this article are the many symptoms cannabis used to treat before the prohibition of cannabis and the scheduling of the medication under the Controlled Substances Act. Cannabis has been used in eastern medicine, for thousands of years, and used to be a prevalent medication in the late 19th and early 20th centuries, and has just recently been re-recognized as an option to treat anorexia associated with human immunodeficiency virus (HIV), nausea and vomiting due to chemotherapy, and various sleep disorders. Cannabis was once a well-recognized medication, but it has been mercilessly slandered by politicians. The rise and fall of cannabis have largely been politically driven pushes, and the plant and its effects deserve further study to examine the scope and efficacy of its therapeutic benefits.

View this review (yellow link) or download:

Nabilone administration in refractory chronic diarrhea- a case seriesDownload

This paper is also stored here: http://bit.ly/2jP1ocV inside the CED Foundation Archive

To explore related information, click the keywords below:

Cannabinoids and autoimmune diseases: A systematic review (Diabetes)

July 14, 2019 Animal Model, Anti-inflammatory properties, Autoimmunity, Blood-Levels, CBD, CED Clinic, Diabetes, Dr Caplan, Future Medicine, Placebo-Controlled, Video

As it stands, there is no cure for Type 1 Diabetes Mellitus. But, some of us in the medical community are starting to wonder if cannabis could be a viable treatment option. Several studies already address this, with impressive findings, and now, A new mouse model study suggests that not only could CBD prevent Type 1 Diabetes, but it seems to also reduce symptoms after onset.

Now researchers must determine the long term effects of CBD treatment. Watch a video summary below:

View this review (yellow link) or download:

Cannabinoids and autoimmune diseases: A systematic review Download

This paper is also stored here: http://bit.ly/2Y1paV5 inside the CED Foundation Archive

To explore related information, click the keywords below:

Cannabidiol Treatment for Parkinson’s Disease

July 1, 2019 Aging, Anti-inflammatory properties, Anxiety, Arthritis, Autoimmunity, Behavior change, Cannabinoids, Cannabis, Cannabis Education, Cannabis Science, CB1, CB2, CBD, Depression, DSM-5, Elderly, Future Medicine, Insomnia, Memory, Muscle Pain, Neuropathy, Parkinson's Disease, Science

Cannabidiol: a hope to treat non‑motor symptoms of Parkinson’s Disease Patients

Cannabidiol (CBD) has recently been postulated as an ideal drug to address the treatment of non-motor symptoms of Parkinson’s Disease (PD) due to its multifaceted mechanism of action. The plethora of effects of CBD includes anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic actions, which improve non-motor symptoms of PD and lift the quality of life for patients coping with the illness. Further research is recommended to garner support for FDA approval.

View this review (yellow link) or download:

Cannabidiol: A hope to treat non‑motor symptoms of Parkinson’s disease patients Download

This paper is also stored here: http://bit.ly/2KXTb0Y inside the CED Foundation Archive

To explore related information, click the keywords below:

Study Reveals that Flavanoids can act as Allergy Medications

June 29, 2019 Aging, Allergy, Anti-inflammatory properties, Autoimmunity, Blood-Levels, Extraction, Flavonoids, Future Medicine, Non-Cannabis Plant, Oral Health, Placebo-Controlled, Science, Terpenes

Anti-histaminic Effects of Resveratrol and Silymarin on Human Gingival Fibroblasts

It has recently been revealed that the flavonoids resveratrol and silymarin have an anti-histaminic effect on human gingival fibroblasts (HGF). HGF are cells that compose part of the gum tissue in the oral cavity. Silymarin and resveratrol were already known to have anti-bacterial and anti-inflammatory properties, but a recently published study has now revealed that silymarin alone and a combination of the two flavonoids both provide novel therapeutic approaches for inflammation due to allergies.

View this review (yellow link) or download:

Anti-histaminic Effects of Resveratrol and Silymarin on Human Gingival Fibroblasts Download

This paper is also stored here: http://bit.ly/2Ff1lhW inside the CED Foundation Archive

To explore related information, click the keywords below:

The Cannabinoid System is a Promising Source of Targets for Treating Pain

June 28, 2019 Addiction, Adverse Effects, Anti-inflammatory properties, Anxiety, Arthritis, Autoimmunity, Blood-Levels, Cannabinoids, Cannabis, Cannabis Science, CB1, CB2, CBD, Citizen Science, Cognition, Elderly, Future Medicine, Memory, Multiple Sclerosis, Muscle Pain, Neuropathy, Occasional Use, Opiates, Overdose, Pain, Placebo-Controlled, Products, Regulation, Science, Stigma, Stress, THC

A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain ECS

The cannabinoid system provides momentum to develop cannabinoid-based medications to treat inflammatory and neuropathic pain as researchers continue to find promising therapeutic targets. These new targets may lead to the formation of novel pain-relief medications that may serve well to alleviate pain for those suffering from cancer, multiple sclerosis, and fibromyalgia. Cannabis-based pain medicine is also being researched for opioid-sparing effects and effectiveness in reducing the necessary dose of opioids.

View this review (yellow link) or download:

A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain ECS Download

This paper is also stored here: http://bit.ly/2FfLorA inside the CED Foundation Archive

To explore related information, click the keywords below: